Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

A Treasure Trove of New Cancer Biomarkers

November 10, 2015 By RIKEN

Biomarkers, which allow diseases to be diagnosed and staged based on relatively non-invasive blood tests, have been identified for several types of cancers, but for most cancers remain elusive. Now, research conducted at the RIKEN Center for Life Science Technologies (CLST) in Japan and the Harry Perkins Institute of Medical Research in Australia has identified a large number of genes that are upregulated in many different types of cancer, opening the door for developing biomarker tests that could be used to detect cancers early, allowing for prompt treatment.

The study, published on November 9 in Cancer Research, made use of two different technologies. First, the team looked at data generated by CAGE technology that was developed at RIKEN as part of the FANTOM project. They examined RNA expression profiles of 225 cancer cell lines and 339 normal cells, and looked for differences in gene expression. They then supplemented this by looking at RNA sequencing data from 4,055 primary tumors and 563 healthy tissues from the Cancer Genome Atlas (TCGA) database, and crossed the two to identify changes that were found in both datasets.

According to Bogumil Kaczkowski of CLST, the first author of the paper, “Using the two different datasets allowed us to make use of the strengths of each. The TCGA data is complicated by the fact that tumor samples are composed of mixture of different cells, while the FANTOM5 CAGE data is from cells grown in cell culture where changes might arise from the culture process. By putting the two together and looking at changes found in both, we have been able to make a robust catalog.”

Based on the work, the researchers were able to identify 128 markers that were consistently perturbed in both datasets in a variety of tumor types. Some of them, such as TOP2A and MKI67, are well-known targets as potential biomarkers. But thanks to the data from FANTOM5, they were also able to find a number of new markers including non-coding RNAs, RNAs derived from repetitive elements and enhancer elements that CAGE technology can identify. In particular, they found that a little known repetitive element called REP522, was upregulated in many cancers.

According to Piero Carninci, one of the leaders of the FANTOM5 consortium and an author of the paper, “The study shows that our CAGE (Cap-Analysis Gene Expression) technology is a powerful tool for cancer marker discovery at the promoter level. We found hundreds of promoters—parts of the genome that initiate expression of a gene—that are upregulated in cancer, and in particular, promoters that overlap with repetitive elements in the genome seem to be upregulated. This is an interesting insight into the development of cancer. We are especially interested in the REP522 element, and would like to determine what role it plays.”

Carninci continues, “It is very rewarding to see that our basic science approach to mapping and understanding regulatory elements of the genome can be translated into discovery that can aid early cancer diagnosis. We hope that researchers will use our findings to identify markers for the many cancer types that currently have no useful markers. It may also be possible to target the genes we have identified as potential drug targets. These targets could potentially help many cancer patients as they are up-regulated in many different types of tumors.”

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 13, 2022
Our Pre-Post-DeviceTalks Boston episode, also MedtronicTalks replay with Gastro CMO Austin Chiang
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech